FDA Approves New Animal Drug Trilostane for Dogs

Summary

The US Food and Drug Administration (FDA) is updating its regulations to reflect the approval of Dechra, Ltd.'s new animal drug application (NADA) for trilostane, a treatment for pituitary-dependent hyperadrenocorticism and hyperadrenocorticism due to adrenocortical tumors in dogs.